Genprex CEO Participates in a Second-Round Live Interview on the “Big Biz Show”
July 30 2020 - 8:16AM
Business Wire
Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a
clinical-stage gene therapy company developing potentially
life-changing technologies for patients with cancer and diabetes,
today announced that its Chairman and Chief Executive Officer,
Rodney Varner, has participated in a second-round live interview on
the “Big Biz Show,” an emmy-award winning nationally syndicated TV
and radio show. A replay of the interview is available for viewing
on the Company’s website at https://bit.ly/2Esvq05.
During this interview, Mr. Varner discusses:
- Genprex’s lead drug candidate, GPX-001, for non-small cell lung
cancer
- How the Company is forging ahead during the COVID-19
pandemic
- Company catalysts coming in the next 18 months
- A recent National Institutes of Health $2.59 million research
grant awarded to its collaborators at the University of Pittsburgh
for its licensed diabetes gene therapy
The Big Biz Show covers current business events,
internet-related issues and other hot topics in the business world.
The Big Biz Show is seen and heard in over 100 million broadcast TV
homes, 150 radio stations in the U.S. and in 175 countries. The
Emmy Award winning show was named by TALKERS Magazine as one of the
“Top 10 Most Influential Financial Shows.”
The Big Biz Show can be seen and heard every weeknight on YouTOO
America Television Network at 8 p.m. ET, the following morning at 7
a.m. ET, and every weekday on BizTalk Radio at 2 p.m. ET.
Additionally, the show can be accessed digitally by visiting
BizTVClub.com, where you can watch the Big Biz Show every weeknight
at 9 p.m. ET.
To watch Mr. Varner’s first live appearance on the Big Biz Show
in June 2020, visit Genprex’s website.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with
cancer and diabetes. Genprex’s technologies are designed to
administer disease-fighting genes to provide new treatment options
for large patient populations with cancer and diabetes who
currently have limited treatment options. Genprex works with
world-class institutions and collaborators to in-license and
develop drug candidates to further its pipeline of gene therapies
in order to provide novel treatment approaches. The Company’s lead
product candidate, Oncoprex™, is being evaluated as a treatment for
non-small cell lung cancer (NSCLC). Oncoprex has a multimodal
mechanism of action that has been shown to interrupt cell signaling
pathways that cause replication and proliferation of cancer cells;
re-establish pathways for apoptosis, or programmed cell death, in
cancer cells; and modulate the immune response against cancer
cells. Oncoprex has also been shown to block mechanisms that create
drug resistance. In January 2020, the U.S. Food and Drug
Administration granted Fast Track Designation for Oncoprex
immunogene therapy for NSCLC in combination therapy with
osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR
mutations whose tumors progressed after treatment with osimertinib
alone. For more information, please visit the Company’s web site at
www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current and planned clinical trials, regarding the
Company’s future growth and financial status and regarding our
commercial partnerships and intellectual property licenses. Risks
that contribute to the uncertain nature of the forward-looking
statements include the presence and level of the effect of our
product candidates, alone and in combination with other therapies,
on cancer; the timing and success of our clinical trials and
planned clinical trials of GPX-001, alone and in combination with
targeted therapies and/or immunotherapies, and whether our other
potential product candidates, including GPX-002, our gene therapy
in diabetes, advance into clinical trials; the success of our
strategic partnerships, including those relating to manufacturing
of our product candidates; the timing and success at all of
obtaining FDA approval of GPX-001 and our other potential product
candidates including whether we receive fast track or similar
regulatory designations; costs associated with developing our
product candidates and whether patents will ever be issued under
patent applications that are the subject of our license agreements.
These and other risks and uncertainties are described more fully
under the caption “Risk Factors” and elsewhere in our filings and
reports with the United States Securities and Exchange Commission.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200730005117/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024